Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think it's worth mentioning that Dr. Lippa presented at the 5th annual installment of the same conference a couple years back, and that RespireRx representatives presented at the inaugural conference and the year two conference as well. So while exposure is a good thing it's probably not worth reading too much into their upcoming presentations in terms of gauging how far along their cannabinoid program is.
https://www.biospace.com/respirerx-pharmaceuticals-inc-announces-that-dr-arnold-lippa-is-an-invited-speaker-at-the-5th-international-cannabinoid-derived-pharmaceuticals-summit
https://markets.businessinsider.com/news/stocks/respirerx-pharmaceuticals-inc-executives-participating-in-the-2nd-annual-international-cannabinoid-derived-pharmaceuticals-summit-1028510435
https://www.marketscreener.com/quote/stock/RESPIRERX-PHARMACEUTICALS-5787161/news/RespireRx-Pharmaceuticals-Inc-Executives-Presenting-at-the-International-Cannabinoid-Derived-Pharma-27731174/
Says it was published the 20th, not sure if it's been posted before.
https://www.tandfonline.com/doi/full/10.1080/17568919.2024.2401312
Logically one would think they would update the public on the status of their OSA program and really the company in general before they bother presenting at this conference....
I mean if the most up to date information related to the company and the OSA program is appraoching a year old, would many attend?
Thanks for additional due diligence. Just more evidence that they are essentially summarizing their entire ampakine portfolio it appears. I am really wondering if they wont end up selling this platform at some point in time similar to what was done years ago with platform. Especially if this phase 2 SCI trial is successful, I think it opens a sh-ton of doors and avenues that a larger company could better navigate.
These look more like preclinical compounds and I would be curious where the company ranks them relative to CX1739 and CX717 which they list as phase 2 level candidates. Are these newer ones just backups, superior or tweaked for different medical indications than SCI/ADHD, etc?
Kind of an interesting presentation topic...
I wonder if the pro's and con's of the EM illiquid market will be discussed in relation to accessing talent and forming partnerships?
CB1, CB2 & Cannabinoid Drug Development Summit.
November 18-20, 2024 | Boston, MA
https://cannabinoid-derived-drug-development.com/speaker/jeff-margolis/
Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers
Daniel P. Radin, Rok Cerne, Jeffrey M. Witkin, Arnold Lippa
First published: 20 September 2024
https://doi.org/10.1002/cpdd.1475
Abstract
AMPA-type glutamate receptors (AMPARs) mediate the majority of fast excitatory synaptic transmission in the mammalian brain. Ampakines, positive allosteric modulators of AMPAR, hold significant potential for the treatment of a wide range of neurological/neuropsychiatric disorders in which excitatory synaptic transmission is compromised. Low-impact ampakines are a distinct subset of ampakines that accelerate channel opening yet minimally affect receptor desensitization, which may explain their lack of seizurogenic effects at therapeutic doses in preclinical models. CX1739 is a low-impact ampakine that has shown efficacy in preclinical studies. The current clinical study examined the tolerability and pharmacokinetics of CX1739 in healthy male volunteers in a 2-part study. Part A was a single dose escalation study (100-1200 mg, 48 patients) and Part B was a multiple dose ascending study (300-600 mg BID for 7-10 days, 32 patients). CX1739 was well tolerated up to 900 mg once daily (QD) and 450 mg twice a day, with the prominent side effects being headache and nausea. Importantly, the half-life of CX1739 was 6-9 hours, and Tmax was 1-5 hours. CX1739 Cmax and AUC were dose-proportional. These findings thus set the stage for further explorations of this drug candidate in phase 2 clinical studies.
Conflicts of Interest
RespireRx Pharmaceuticals is developing CX1739 for the treatment of opiate-induced respiratory depression, ADHD, and spinal cord injury. Daniel Radin, Rok Cerne, Jeffrey Witkin, and Arnold Lippa are associated with RespireRx, where Arnold Lippa is acting CEO, and Daniel P. Radin, Rok Cerne, and Jeffrey M. Witkin are non-paid researchers who occasionally conduct studies on these compounds.
Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763
Daniel P Radin, Sheng Zhong, Rok Cerne, Mohammed Shoaib, Jeffrey M Witkin & Arnold Lippa
Received 28 May 2024, Accepted 02 Sep 2024, Published online: 20 Sep 2024
Cite this article
https://doi.org/10.1080/17568919.2024.2401312
Abstract
Aim: AMPA-glutamate receptor (AMPAR) dysfunction mediates multiple neurological/neuropsychiatric disorders. Ampakines bind AMPARs and allosterically enhance glutamate-elicited currents. This report describes the activity of the water-soluble ampakine CX1942 prodrug and the active moiety CX1763.
Results: CX1763 and CX1942 enhance synaptic transmission in hippocampi of rats. CX1763 increases attention in the 5CSRTT in rats and reduces amphetamine-induced hyperactivity in mice. CX1942 potently reverses opioid-induced respiratory depression in rats. CX1942/CX1763 was effective at 2.5–10 mg/kg. CX1763 lacked epileptogenicity up to 1500 mg/kg in rats.
Conclusion: These data document that CX1942 and CX1763 are active and without prominent side effects in multiple pre-clinical assays. CX1942 could serve as a prodrug for CX1763 with the advantage of high water solubility as in an intravenous formulation.
Article highlights
The water-soluble glycine ester pro-drug of CX1763, CX1942 is potent and active against alfentanil-induced respiratory depression in vivo
CX1942 and CX1763 produce a durable increase in hippocampal EPSP in vivo
CX1763 increases metrics of attention in rodents while reducing hyperactivity associated with amphetamine, indicating multiple potential benefits for ADHD treatment
CX1763/CX1942 is therapeutically active at doses of 2.5–10 mg/kg and CX1763 lacks epileptic and fatal toxicities up to 1500 mg/kg, demonstrating a notable safety margin, justifying further preclinical and clinical explorations
I’ll take even just 0.54 per share
Folks, From the PhD thesis abstract that I posted yesterday:
1. GL-II-73, exhibits promising results in rodent models for depression treatment. It demonstrates excellent pharmacokinetic characteristics and displays antidepressant and anxiolytic effects in mice without inducing sedation or motor impairment typically associated with benzodiazepine drugs. Furthermore, it shows improved cognitive effects, which are crucial in treating depression or schizophrenia. Recent studies indicate that administering a single dose of GL-II-73 within 30 minutes can reverse stress-induced or age-related working memory deficits in old mice, restoring their performance levels to approximately 80-90%, nearly equivalent to those of young mice. Typically, old or stressed young mice perform at about 50-60%. Moreover, there was a remarkable reversal of brain cell shrinkage (dendrites and spines) in older mice, typically associated with aging, to a level similar to that of young mice. This exciting development occurred after two months of administering GL-II-73 in the drinking water of the older mice.
2. KRM-II-81 bioisosteres designed and synthesized, KPP-III-34 (8-bromo substituted imidazodiazepine) demonstrated improved target site (brain) exposure and metabolic stability in plasma and brain, leading to enhanced oral bioavailability ideal for pre-clinical studies. KPP-III-34 exhibited exceptional efficacy in various epilepsy models, including Lamotrigine-resistant seizure models, non-convulsive status epilepticus models, and chronic seizure models, via intraperitoneal (i.p.) or oral v administration in animals (mice or rats). Additionally, KPP-III-34 demonstrated a clean toxicity profile and selectively bound to the rat brain benzodiazepine receptor site without undesired binding to other receptors, according to PDSP (UNC) screens.
3. With these improved synthesis methods, we can now supply our collaborators with large quantities of these three a2/3-subtype selective GABAARs PAMs(KRM-II-81,KPP-III-34,DS-II-73 and MP-III-024 efficiently and with high quality.
RE 1 and 2: If show these same tolerance and efficacy in the clinic, will be, (dare I say it?) a societal change on the order of the industrial revolution and electronics revolution (including AI) will be upon us.. WE are on the verge of countering many cogitative disabilities include brain aging (memory loss). RE 3: manufacturing these molecules apparently will not prevent this revolution ! IMO, of course!!!
A long way from that dream, but...
These assets have that potential. This company needs to get current and secure some level or round of financing to support BOTH ampakine and gabakine programs as they are both moving into human clinicals where exponential leaps in valuation occur. They need to grow the awareness and investor base to be in position to leverage their valuable assets to obtain the resources and partnerships to continue exploiting the assets through various clinical trials and new medical indications. The better the foundation the more equity in the assets they retain until a point in time BP takes over.
Serious endeavours and assets require serious people where appearance matters. Looking forward to watching this company blossom in the coming months and well into 2025 as these assets enter various human clinical trials.
Looks like licensed to a different company for different medical indications. That company looked like it raised over 5 million in a financing round.
RSPI's gabakine KRM-ll-81 is much further advanced with past preclinical efforts and the recent IND enabling preclincals with the NIH leading into now a consulting firm hiring and likely grant support coming. Considering the size of both epilepsy and pain mitigation markets, this is good info to see how something less positioned raised a chunk of capital.
I guess I am wondering if the ATT hiring for the gabakine program will lead into grant funding for both epilepsy and pain phase 1 clinicals run congruently and will this be a lead in to seek additional capital to support and possibly spin the gabakine program seperate from the ampakine activities?
Hopefully something new surfaces on the OSA program before they bother speaking at a conference..
This kind of builds on past post and ties the two companies
https://uwm.edu/news/cook-recognized-for-scientific-leadership-in-biohealth-research/
https://www.bioforward.org/2022/08/16/bioforward-recognizes-scientific-and-business-success-with-annual-wisconsin-biohealth-awards-2/
https://www.bioforward.org/team_members/wisconsin-biohealth-summit-awardee-james-cook/
E.S., T.D.P and J.C. are co-inventors or listed on US patent applications that cover GABAergic ligands, including GL-II-73, and their use in brain disorders. E.S. is co-founder and CSO, and T.D.P is Director of Operation of DAMONA Pharmaceuticals, a biopharmaceutical company dedicated to treating cognitive deficits in brain disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380722/
This is all I really found , but with what they are offering it is looking like it could be in the mix. GLTA
Uncertain if GL-II-73 is licensed to RSPI. I could find no link
Extrasynaptic localization is essential for a5GABAA receptor modulation of dopamine system function
Alexandra M McCoy , Thomas D Prevot Md Yeunus Mian , Dishary Sharmin , Adeeba N Ahmad 6, James M Cook , Etienne L Sibille , Daniel J Lodge
DOI: 10.1523/ENEURO.0344-23.2023
Abstract
Dopamine system dysfunction, observed in animal models with psychosis-like symptomatology, can be restored by targeting Gamma-Aminobutyric Acid type A receptors (GABAAR) containing the a5, but not a1, subunit in the ventral hippocampus (vHipp). The reason for this discrepancy in efficacy remains elusive; however, one key difference is that a1GABAARs are primarily located in the synapse, whereas a5GABAARs are mostly extrasynaptic. To test whether receptor location is responsible for this difference in efficacy, we injected a small interfering ribonucleic acid (siRNA) into the vHipp to knock down radixin, a scaffolding protein that holds a5GABAARs in the extrasynaptic space. We then administered GL-II-73, a positive allosteric modulator of a5GABAARs (a5-PAM) known to reverse shock-induced deficits in dopamine system function, to determine if shifting a5GABAARs from the extrasynaptic space to the synapse would prevent the effects of a5-PAM on dopamine system function. As expected, knockdown of radixin significantly decreased radixin-associated a5GABAARs and increased the proportion of synaptic a5GABAARs, without changing the overall expression of a5GABAARs. Importantly, GL-II-73 was no longer able to modulate dopamine neuron activity in radixin-knockdown rats, indicating that the extrasynaptic localization of a5GABAARs is critical for hippocampal modulation of the dopamine system. These results may have important implications for clinical use of GL-II-73, as periods of high hippocampal activity appear to favor synaptic a5GABAARs, thus efficacy may be diminished in conditions where aberrant hippocampal activity is present.Significance Statement Currently available treatments for psychosis, a debilitating symptom linked with several brain disorders, are inadequate. While they can help manage symptoms in some patients, they do so imperfectly. They are also associated with severe side effects that can cause discontinuation of medication. This study provides preclinical evidence that the drug, GL-II-73, possesses the ability to modulate dopamine activity, a key player in psychosis symptoms, and further provides some mechanistic details regarding these effects. Overall, this work contributes to the growing body of literature suggesting that GL-II-73 and similar compounds may possess antipsychotic efficacy.
Sorry for the last link , here it is but it is the same they put out back in Jan 16 2024 nothing new was added . Have a great weekend everyone GLTA
https://www.primarymarkets.com/wp-content/uploads/2024/01/Resolution-RX-new-slide-deck-16-January-2024-NEW-FINAL-FINAL.pdf
wow, that would be a dream come true!!! to a big pharma, that is chump change lol
I know, and I’m not worried. I’m green still as my average is on trips, hopefully we all get rewarded b4 this year ends .
"www.meixatech.com/cv.pdf"
Impressive. Congrats for all you've accomplished.
Did you take any legal action against Martinez? You refer to his email as libelous but isn't it a private communication?
Well got a reply send me questions and I will include back to them , keep in mind that they can't detail insider info please
Paul Franklin
From:
pf@primarymarkets.com
To:
xxxx
Thu, Sep 19 at 11:19 PM
Hi xxxx
I’m speaking with the company (Jeff Margolis and Arnold Lippa) on Tuesday next week so I can have some of your questions answered for you.
Attached is ResolutionRX’s investor presentation from the beginning of this year. I’ll be receiving the updates next week so I’ll pass these on.
As mentioned in the previous correspondence, we’re happy to make an introuction with the company’s management once we’ve recevied the company’s current updates.
Best Regards,
Paul
data:image/jpeg;base64,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
I have sent off for the presentation pkg , we will see what it has in it
At current 983M O/S roughly 2.54/share
Yeah that ain’t happening but it ain’t hard do the math. We are at 983m o/s times it by any share price and u got ur market cap
What would a 2.5 billion dollar market cap look like in price/share?
Probably easier on the old brain to just go back to popcorn and pompoms...
Have a good weekend.
Yes a science driven team, however they are a publicly traded company and should have or had business end people associated to match the progress on the science end. Having sustained awareness and value only opens up the doors to opportunities in my mind. Hopefully a plan is in place to change that imbalance.
Actually, it doesn't surprise me. As a scientist (www.meixatech.com/cv.pdf) my focus has always been on science. Money, although important (according to my wife) has never been a priority for me. The RSPI principals up to recently have totally focused on the science (and licensing). Using graduate students (= science slaves) for the research is quite cost-effective. I believe their business model has been to share molecules, but for all groups to agree to adhere to a licensing. Thus, RSP.I has created, a strong science foundation, the value of which could be in the multibillions (IMO)
Thats why I say 2025 is going to be a big year.
Imagine the Phase 2 SCI trial be very successful. How much does that compound alone be worth alongside the entirety of the ampakine platform that may yield benefits for ADHD and other orpan indications.
On top of that there is likely a phase 1 trial with grant money to occur that has implications for both epilpesy and pain indications both of which are massive markets in need and high profile.
Postulating a 2.5 Billion market valuation seems so far fetched....
Of course, a puny 1.1 million market valuation is also far fetched....
I think this gap will be bridged significantly in the coming months and subsequent year.
One of the curiosities I have with the NIH Tier 3 preclincals is does this translate to epilepsy models or is there a different organization that conducts those.
Reason I ask is much of the past work with KRM-ll-81 showed significant promise for epilepsy which needs improved care badly. However, the intent of the NIH preclinicals revolved around pain and mitigating the opioid crisis. Would the tier 3 preclinicals possibly cover both medical indications?
What I am really wondering is the new consultant firm being hired for the gabakine program would they be seeking grant support for BOTH a phase 1 pain trial and a phase 1 epilespy trial congruently?? Or could another interested party be looking at this compound for a specific indication?
Yes it boggles one mind all the publications and preclinical and clinical efforts/success and yet none of this is coalesced into a nice website for potential investors and collaborators to review. It is hard to understand the claims that being on the OTC and blah blah make it difficult to raise funds and have liquidity when communication, awareness and presentation of the company is lacking.
bigtalan: I am now, more than ever, thinking your estimate of RSPI's pipeline value of 2.5 B USD is quite possible..
Folks, There is still a lot more to the GABAkines platform!!! A PhD thesis abstract, which oddly will not be published until 2026. Yes, GL-II-73 appears to be licensed to RSPI. RSPI appears to "own" most of these GABA molecules.
DESIGN AND SYNTHESIS OF ACHIRAL AND CHIRAL GABA RECEPTOR SUBTYPE SELECTIVE LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AS WELL AS EPILEPSY AND ASTHMA
PRITHU MONDAL, University of Wisconsin-Milwaukee
Abstract
DESIGN AND SYNTHESIS OF ACHIRAL AND CHIRAL GABA RECEPTOR SUBTYPE SELECTIVE LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AS WELL AS EPILEPSY by Prithu Mondal The University of Wisconsin-Milwaukee, 2024 Under the Supervision of Professor James M. Cook Gamma-aminobutyric acid type A receptors (GABAAR) are pentameric ligand-gated chloride ion channels located in the membranes, which respond to gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter within the central nervous system (CNS). Benzodiazepines (BZDs) bind to the extracellular interface of the a+?2-subunits of GABAAR. The binding of ligands to different subunits of GABAA receptors, particularly at a1-6ß2/3 ?2 ion channels, can influence a broad spectrum of brain functions. The a1-subtype selective ion channels of GABAARs contribute to sedative, ataxic, amnesic, anticonvulsant, and addictive effects, which should generally be avoided, except for the desirable anti-anxiety and anticonvulsant effects, when designing ligands targeting this BZ allosteric modulatory site. GABAARs containing a2/3 subunits have been associated with anxiolytic, anticonvulsant, and antinociceptive activities. At higher doses, muscle relaxation may be mediated by interactions with a3 subtypes. It is well-established that a5-containing GABAARs play roles in cognition, learning, and memory processes. The dysregulation of GABA activity at a5 subtypes on GABAAR is implicated in the pathophysiology of various CNS disorders, including schizophrenia, major depressive disorder (MDD), bipolar disorder, and specific anxiety disorders like OCD. Additionally, a5 subtypes in the lung play a significant role in exploring potential new treatments for asthma. Drawing from the "privileged imidazodiazepine (IMZD) structures" derived from the unified pharmacophore model of Milwaukee, this research endeavors to design, synthesize, and assess the biological activities of over 120 novel chiral GABAAR a2/a3/a5 or a5 subtype-selective imidazodiazepines (IMDZs) related to SH-053-2'F-R-CH3 and its enantiomer iii SH-053-2'F-S-CH3. The objective is to develop new analogs with enhanced metabolic stability while retaining the desired biological properties with minimal or no side effects for the treatment of CNS disorders and asthma. A subset of compounds from the a5 subtype-selective group demonstrates anxiolytic, antidepressant, and pro-cognitive properties, making them promising candidates for treating major depressive disorders. Approximately 30 grams of a lead compound (GL-II-73) and several analogs were synthesized and assessed. The a5-selective chiral lead amide, GL-II-73, exhibits promising results in rodent models for depression treatment. It demonstrates excellent pharmacokinetic characteristics and displays antidepressant and anxiolytic effects in mice without inducing sedation or motor impairment typically associated with benzodiazepine drugs. Furthermore, it shows improved cognitive effects, which are crucial in treating depression or schizophrenia. Recent studies indicate that administering a single dose of GL-II-73 within 30 minutes can reverse stress-induced or age-related working memory deficits in old mice, restoring their performance levels to approximately 80-90%, nearly equivalent to those of young mice. Typically, old or stressed young mice perform at about 50-60%. Moreover, there was a remarkable reversal of brain cell shrinkage (dendrites and spines) in older mice, typically associated with aging, to a level similar to that of young mice. This exciting development occurred after two months of administering GL-II-73 in the drinking water of the older mice. These findings, presented by collaborator Dr. Etienne Sibille in an interview with the BBC, have resulted in three papers and two patents. There is optimism that the CAMH group led by Sibille can advance this project to human trials within two years, as proposed. Ongoing research by multiple groups continues to explore the potential of these key compounds, including their application in other CNS neurodegenerative diseases. Motivated by the results of GL-II-73( 2'F), a similar analogue was synthesized with the new analogue is different by a single atom (2'Cl). PM-II-26 (2 Cl GL-II-73) showed promising data as an antidepressant and a procognitive compound and further test is going on..Approximately 5g grams of this ligand has been synthesized in good yield to support various biological assays by our collaborators. To further test the 2'Cl series more amides and oxadiazoles were made. One of the oxadiazole PM-II-84E showed promising data as a precognitive compound even at slightly higher doses with no sedation and ataxia. This compound is a very good candidate for further testing. To enhance the iv development of new a2/3 subtype selective agents for treating anxiety disorders, neuropathic pain, epilepsy and asthma we implemented an improved large-scale synthetic method for GL-I-54, MP-III-023, PM-II-26 and PM-II-84E. These ligands, known for their anxiolytic, anticonvulsant, and antinociceptive properties, were synthesized under milder conditions with significantly improved yields. Epilepsy stands as one of the most prevalent neurological conditions, contributing significantly to neurological disability. Approximately 1-2% of the population grapples with this disorder, with about 33% enduring refractory epilepsy. While numerous drugs, including widely prescribed benzodiazepines like Valium and Xanax, are available for neurological disorders such as epilepsy and anxiety, they unfortunately lead to tolerance development within approximately three days, rendering them ineffective. Benzodiazepines bind to the a and ? interface of the gamma-aminobutyric acid type A (GABAA) receptor non-selectively, resulting in adverse effects, including tolerance, addiction, sedation, ataxia, somnolence, and confusion. For the first time, agents like HZ-166 and XHe-II-053, developed in Milwaukee, emerged as a2/a3 receptor subtype-selective ligands with anxiolytic and anticonvulsive activity, devoid of undesired side effects such as sedation and ataxia. However, the ester function in XHe-II-053 and HZ-166 could undergo metabolism into less active corresponding carboxylic acids, resulting in poor exposure, high clearance, and low blood-brain barrier penetration. The replacement of the ester with heterocycles (oxazoles and oxadiazoles) improved metabolic stability and pharmacokinetics, leading to the development of the clinically progressing non-sedating anticonvulsant KRM-II-81. As backup compounds, analogs were designed and synthesized based on the structure of KRM-II-81. Following docking in the human full-length heteromeric a1ß3?2 GABAA receptor subtype CryoEM structure (6HUO), several novel oxazole and oxazoline analogs exhibited potent anticonvulsant activity with enhanced in-vivo and in-vitro stability, free from cytotoxicity, sedation, ataxia, and loss of righting response. Among the many novel KRM-II-81 bioisosteres designed and synthesized, KPP-III-34 (8-bromo substituted imidazodiazepine) demonstrated improved target site (brain) exposure and metabolic stability in plasma and brain, leading to enhanced oral bioavailability ideal for pre-clinical studies. KPP-III-34 exhibited exceptional efficacy in various epilepsy models, including Lamotrigine-resistant seizure models, non-convulsive status epilepticus models, and chronic seizure models, via intraperitoneal (i.p.) or oral v administration in animals (mice or rats). Additionally, KPP-III-34 demonstrated a clean toxicity profile and selectively bound to the rat brain benzodiazepine receptor site without undesired binding to other receptors, according to PDSP (UNC) screens. The facile synthesis of KPP-III-34 was successfully executed on a large scale, requiring no column chromatography or toxic and expensive palladium. KPP-III-34 emerges as a potent and safe backup anticonvulsant agent for the treatment of epilepsy, complementing the clinically progressing KRM-II-81 (ETSP, NINDS). With these improved synthesis methods, we can now supply our collaborators with large quantities of these three a2/3-subtype selective GABAARs PAMs(KRM-II-81,KPP-III-34,DS-II-73 and MP-III-024 efficiently and with high quality. These compounds have demonstrated anxiolytic, anticonvulsant, and antinociceptive effects in numerous animal tests. The availability of gram quantities of these compounds enables further investigation into their ADME toxicity and behavior assays, including those in primates. This facilitates studies in animal models for anxiety, epilepsy, and neuropathic pain, which require substantial amounts of compounds. Additionally, it allows for the execution of long-term safety studies necessary for regulatory approval by the FDA
Just an example of the famous phrase....
"The stock market is a device for transferring money from the impatient to the patient."
While non-investors were exiting their positions leading up to this now EM illiquid market, investors were happily absorbing those same shares. All the due diligence is right out there on this one. In filings, in commentary, etc. Applying a little logic and recognize that the golden goose will eventually lay an egg and patient enough to understand it will lay another and another.... Well you see the point.
Just crumbs. Nobody has access to accumulate shares and nobody is giving away shares for peanuts.
Not to say some "experts" wont accumulate shares here and start buying at any prices. Heck I think wasnt there a 25 m bid get filled around .002 right before going EM or something like that?
This company has the goods for a fantastic story. We are just waiting for them to open the curtain.
Yeah they letting us break 002 lol
Not good
3,110,000 0.002
10,000 0.0004
Agree. A few crumbs here or there can be the difference between a 200% day and a sliced in half day. Nothing to really glean from trading on the EM.
I do think anticipation will begin to grow as we are approaching Q4 and really with seeking grant funding for KRM-ll-81 as another government funded clinical may surface at any time and the Cx-1739 trial can kick off any time as well I would think among a host of other potential opportunities in the ampakine program.
Considering they cleaned up the language of the preferred shares, I would speculate there might be a funding round in the works. Obviously, they have stated they are seeking funds to rectify the EM status, but clearly also needed to support the platforms into multiple human clinicals. It will be curious if any bigger purse strings take an equity position. I can see RSPI wanting to get through a clinical trial with both the ampakine and gabakine programs before entertaining any big JV/license agreement since a successful trial exponentially increases value of the drug candidate and negotiating power.
The due diligence and early success of the pipeline assets are extremely compelling, we know that. There has been radio silence from the company while we observe progression with publications, opportunity to improve communications and witness time ticking on by closer to "event" timeframes such as the DOD trial and OSA conference, etc. When they begin to tell their story here, it won't be a 1 week wonder stock, this has the making of monster than grows continuously through multiple clinical trials over the next 3-9 months... In my opinion only. Good luck to all.
What’s bid and ask now?
I’m with you DT… it’s a waiting game at this point. Patience is a must… Have a good one brother!
I didn't expect it to hold while on the expert market. Once they file that's when the excitement begins for us who decided to ride this out. In the meantime I do enjoy the green days when we get them just to make the portfolio look better. :)
Maybe you should inquire as to why there has been zero communication related to the OSA program in quite some time. Kinda hard to invest or believe in something when the information flow is stale or non-existant!
At least we know whats coming up next for both the ampakine and gabakine platforms. Although the ResolutionRx website appears much more up to date than the RespireRx website...
Yeah it will be interesting to see how they structure these assets. Could we see either or both the ampakine or gabakine platform spun out into its own entity similar to the OSA platform? Will there be an intermediate route of funding to get them through phase 2 SCI trial and/or a phase 1 trial for KRM-ll-81 where successful trials exponentially increase valuation? One can imagine all types of negotiations ongoing.
I dont really see where the EM/no liquidity and allowing company to be way undervalued helps in this regards and just as important provide any flexibility to acquiring resources and partnerships they need to move through clinical trials..... but maybe they have that all ready to go and we are just waiting for them to unveil all?
Followers
|
347
|
Posters
|
|
Posts (Today)
|
9
|
Posts (Total)
|
51658
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |